Novo Nordisk builds in haemophilia with Bluebird Bio gene editing dealAnxious not to be left behind in the haemophilia market, Novo Nordisk has forged an alliance with Bluebird Share XNovo Nordisk builds in haemophilia with Bluebird Bio gene editing dealhttps://pharmaphorum.com/news/novo-nordisk-builds-in-haemophilia-with-bluebird-bio-gene-editing-deal/
bluebird presents long-term data from CALD gene therapybluebird bio has produced updated data from its gene therapy for the rare genetic neurological disease cerebral adrenoleukodystrophy Share Xbluebird presents long-term data from CALD gene therapyhttps://pharmaphorum.com/news/bluebird-presents-long-term-data-from-cald-gene-therapy/
bluebird offers instalment payments for Zynteglo gene therapybluebird bio is pricing its thalassaemia gene therapy Zynteglo at €1.57 million ($1.8 million) in Europe, but with Share Xbluebird offers instalment payments for Zynteglo gene therapyhttps://pharmaphorum.com/news/bluebird-offers-instalment-payments-for-zynteglo-gene-therapy/
Bringing gene therapies to marketDoug Danison, vice-president, head of access, value and evidence strategy at bluebird bio, a gene therapy company, looks Share XBringing gene therapies to markethttps://deep-dive.pharmaphorum.com/magazine/access-and-commercialisation/bluebird-bio-gene-therapies-market/
bluebird claims first approval for gene therapy Zynteglo in EUbluebird bio has its first ever product approval, getting a green light from the EMA for Zynteglo, its Share Xbluebird claims first approval for gene therapy Zynteglo in EUhttps://pharmaphorum.com/news/bluebird-claims-first-approval-for-gene-therapy-zynteglo-in-eu/
Gene therapy and market access: the pharmaphorum podcastFor episode 10 of the pharmaphorum podcast I spoke to Nicola Redfern, who’s general manager at bluebird bio Share XGene therapy and market access: the pharmaphorum podcasthttps://pharmaphorum.com/podcast/gene-therapy-market-access
Deep Dive: Access and CommercialisationIn this issue of Deep Dive we explore the ever present issues of market access and commercialisation, analysing Share XDeep Dive: Access and Commercialisationhttps://pharmaphorum.com/digital/pharma-access-commercialisation/
bluebird bio gets CHMP nod for gene therapy ZyntegloA European Medicines Agency advisory panel has recommended a conditional approval for Zynteglo, bluebird bio’s lead gene therapy Share Xbluebird bio gets CHMP nod for gene therapy Zynteglohttps://pharmaphorum.com/news/bluebird-bio-gets-chmp-nod-for-gene-therapy-zynteglo/
Gene addition – a new chapter in treating rare diseasesThe scientific advancements of the past 30 years have transformed our understanding of the potential of gene therapy and Share XGene addition – a new chapter in treating rare diseaseshttps://pharmaphorum.com/views-and-analysis/gene-addition-a-new-chapter-in-treating-rare-diseases/
